Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Esteve Pharmaceuticals S A is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, reflecting a spread across different specialized examination groups. The prosecution involves distinct examiners, each handling a pending case. This structure requires the company to navigate different administrative standards and technical perspectives within the patent office.
BORI, IBRAHIM D is the busiest examiner for the portfolio, currently overseeing 1 pending office action. With 2 pending office actions in 2 distinct art units, the company must adapt its strategy to the specific requirements of each division. This distribution suggests that the distinct examiners may provide different perspectives on the company's Biotechnology & Pharmaceuticals filings. Practitioners should monitor these cases to identify any divergent trends in examiner feedback that could impact the broader intellectual property strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | BORI, IBRAHIM D | — |
| 17968253 | CO-CRYSTALS OF TRAMADOL AND COXIBS | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | BORI, IBRAHIM D | 1629 | §103DP | Non-Final OA | — | Pending | Mar 18, 2024 |
| 17968253 | CO-CRYSTALS OF TRAMADOL AND COXIBS | LEE, WILLIAM Y | 1623 | DP | Final Rejection | — | Pending | Oct 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial